Senthil has made over 2 trades of the Axovant Gene Therapies stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 391 units of AXGT stock worth $9,896 on 1 April 2019.
The largest trade he's ever made was selling 406 units of Axovant Gene Therapies stock on 7 January 2019 worth over $5,270. On average, Senthil trades about 133 units every 14 days since 2019. As of 1 April 2019 he still owns at least 126,886 units of Axovant Gene Therapies stock.
You can see the complete history of Mr. Sundaram stock trades at the bottom of the page.
Senthil Sundaram serves as Independent Director of the Company. Mr. Sundaram became the Chief Executive Officer and director of Terns Pharmaceuticals, Inc., clinical-stage pharmaceutical company. Mr. Sundaram served as the Chief Financial Officer of Nightstar Therapeutics plc, a clinical-stage gene therapy company, from April 2017 to June 2019, when it was acquired by Biogen, Inc., a multinational biotechnology company. While at Nightstar, Mr. Sundaram led a number of private and public offerings, including its initial public offering, and a variety of business development efforts including the M&A process that resulted in the acquisition by Biogen. From February 2013 to April 2017, Mr. Sundaram served in a variety of positions at Intercept Pharmaceuticals, Inc., a biopharmaceutical company, including most recently as its Vice President and head of business development. Prior to joining Intercept, from 2000 to 2013, Mr. Sundaram worked in the healthcare investment banking groups at Lehman Brothers Inc., Barclays Capital Inc., Citigroup Global Markets Inc. and Lazard Ltd. Mr. Sundaram earned a B.S. in Computer Engineering and a B.A. in Economics from Brown University.
As the Independent Director of Axovant Gene Therapies, the total compensation of Senthil Sundaram at Axovant Gene Therapies is $114,389. There are 6 executives at Axovant Gene Therapies getting paid more, with Pavan Cheruvu having the highest compensation of $2,868,750.
Senthil Sundaram is 42, he's been the Independent Director of Axovant Gene Therapies since 2019. There are 5 older and 3 younger executives at Axovant Gene Therapies. The oldest executive at Axovant Gene Therapies Ltd. is Atul Pande, 66, who is the Lead Independent Director.
Senthil's mailing address filed with the SEC is 203 Crescent St Ste 303, Waltham, MA 02453, USA.
Over the last 6 years, insiders at Axovant Gene Therapies have traded over $0 worth of Axovant Gene Therapies stock and bought 5,401,703 units worth $20,204,515 . The most active insiders traders include Sciences Ltd. Roivant, Andrew Lo, and Associates Gp Llcqvt Financ.... On average, Axovant Gene Therapies executives and independent directors trade stock every 65 days with the average trade being worth of $1,890,596. The most recent stock trade was executed by Atul Pande on 8 July 2020, trading 10,000 units of AXGT stock currently worth $27,300.
Axovant Gene Therapies Ltd., a clinical-stage company, develops gene therapies for neurodegenerative diseases. The company's product pipeline includes AXO-Lenti-PD program, an in vivo lentiviral gene therapy for the treatment of Parkinson's disease, which is in Phase II clinical trials; the AXO-AAV-GM1 program for the treatment of GM1 gangliosidosis is in Phase I/II clinical trials; and the AXO-AAV-GM2 program for the treatment of GM2 gangliosidosis that is in Phase I/II clinical trials. It has a license agreement with Oxford BioMedica (UK) Ltd.; license and collaboration agreement with Benitec Biopharma Limited; exclusive license agreement with The University of Massachusetts Medical School; and collaboration agreement with Invitae Corporation. The company was formerly known as Axovant Sciences Ltd. The company was founded in 2014 and is based in London, the United Kingdom.
Axovant Gene Therapies executives and other stock owners filed with the SEC include: